Neurology’s prior-authorization burden has a defining feature: the appeals timeline. For migraine — the highest-volume neurological condition in most practices — a denied CGRP antibody or Botox authorization doesn’t resolve in days. The Association of Migraine Disorders has documented appeal timelines of 60 to 90 days, during which the patient remains on whatever they were on before.
For a chronic-migraine patient averaging 15 or more headache days per month, that’s two to three months of preventable attacks while an approval grinds through a payer’s internal process.
The numbers in neurology
Migraine-specific data from the Association of Migraine Disorders:
- 60–90 days to resolve an appealed CGRP monoclonal antibody or onabotulinumtoxinA denial.
- Multiple conventional preventives typically required to fail first before CGRP approval — even when contraindicated.
These ride on top of the burden every physician reports: 39 authorizations per week, roughly 13 hours lost to them, 93% saying PA delays necessary care, and 82% reporting that PA can lead patients to abandon treatment (AMA 2024). In neurology, that general friction attaches to a disease population where treatment interruptions are measured in migraine days.
Why neurology is different
- Step therapy by design. Payers require documented failure of older preventives (propranolol, amitriptyline, topiramate, valproate) before approving a CGRP antibody — independent of whether those agents are tolerated or appropriate for the patient. Documenting failure across multiple agents in the payer’s required format is the core burden.
- Botox’s separate PA path. OnabotulinumtoxinA for chronic migraine requires its own documentation: ≥15 headache days per month, with ≥8 of them migraine, sustained over three months. Each payer sets its own threshold for how this must be demonstrated.
- MS disease-modifying therapies. Beyond migraine, neurologists managing multiple sclerosis contend with PA on high-cost disease-modifying therapies, each with its own formulary tier and step-therapy rules.
- Long appeal windows. A 60-to-90-day appeal isn’t a hard denial — it’s the cost of paperwork. Most appeals succeed; the timeline is the problem.
What it costs
The clearest cost is migraine days that didn’t need to happen. When the preventive that works requires a 90-day appeal to reach, the patient is accumulating attacks, each with its own burden of medication overuse, lost productivity, and downstream care. For the practice, the operational cost is staff hours assembling step-therapy histories and maintaining appeal follow-up — at roughly $10.81 per manually processed authorization (CAQH 2023) — on a high-volume preventive drug class where the outcome was rarely in doubt.
How to cut the wait
The CGRP and Botox authorization packet is structured documentation: prior medications, duration, outcomes, headache-day counts. Artificer Health:
- Assembles the step-therapy record from the chart — prior preventives, trial duration, discontinuation reason, and the disease-burden documentation each payer requires.
- Matches it to the payer’s criteria so the first submission meets that specific payer’s step-therapy threshold — minimizing the back-and-forth that creates the 60-to-90-day appeal window in the first place.
- Tracks re-authorizations for ongoing preventive therapy so a maintenance approval never lapses while the next round of appeals is pending.
A first-pass approval in minutes doesn’t just save staff time. For a chronic-migraine patient, it’s the difference between starting the drug this week and starting it three months from now.
Further reading: CGRP Prior Authorization Guide: Requirements by Drug and Payer (2025–2026) — step therapy criteria, diagnosis thresholds, and payer-specific variations for all 7 FDA-approved CGRP drugs.
Sources: Association of Migraine Disorders (PA and appeal timelines for CGRP / onabotulinumtoxinA); AMA 2024 Prior Authorization Physician Survey (n=1,000); CAQH 2023 Index.